Nebraska medication-management research study gets NACDS Foundation grant
ARLINGTON, Va. — A university research project to look at the potential effects on patient health of incorporating medication management strategies into existing care teams has won a grant from the National Association of Chain Drug Stores’ philanthropic arm.
The NACDS Foundation said it gave the University of Nebraska Medical Center one of three research grants for the project, which will look at the effects of the strategies when they’re incorporated into teams such as medical homes and accountable care organizations.
"Coordinated patient-centered models are promising forums to drive quality and improve patient outcomes while also reducing public health costs," NACDS Foundation president Kathleen Jaeger said. "The primary medical intervention for most patients is medication therapy. Thus, by incorporating medication management strategies into emerging care models, we hope to optimize therapies and evaluate patient outcomes. We are pleased to award this research grant to the University of Nebraska Medical Center in alliance with Blue Cross and Blue Shield of Nebraska, their medical homes and community pharmacy Walgreen Co."
The research will focus on patients with high blood pressure and Type 2 diabetes from around Nebraska during a two-year period, using the Nebraska Health Information Initiative, a statewide bilateral information sharing portal that will allow physicians and pharmacists to share data across clinical settings.
"This research seeks to improve the health and wellness of Nebraskans by better coordinating care between pharmacists and physicians," lead researcher, chairman of the Innovation in Community Pharmacy Practice Network and University of Nebraska Medical Center professor Donald Klepser said. "Research shows that when pharmacists and physicians team up, better care is delivered at lower cost. We believe this project will lead to major improvements in the way care is delivered in communities throughout the state."
Katz Group Canada appoints Sharon Driscoll as EVP, CFO
MISSISSAUGA, Ontario — The company that operates Canada’s Rexall and Rexall Pharma Plus retail pharmacy chains has hired on a former Sears Canada executive.
Katz Group Canada announced Monday the appointment of Sharon Driscoll as EVP and CFO.
Driscoll previously served as SVP finance and CFO for Sears Canada and has worked in financial leadership positions in retail for more than 25 years. Before Sears, she worked in several senior-level positions at Loblaw Cos. Ltd., including SVP corporate development. Driscoll is a chartered accountant and graduated with honors from Queen’s University.
"Sharon’s more than two decades of retail leadership experience will make her a tremendous addition to the Rexall management team," Katz Group Canada CEO Frank Scorpiniti said. "Throughout her career, Sharon has demonstrated a capacity to identify strategic growth opportunities as well as the ability to achieve efficiencies, and we are excited to have her continue that record of success as a member of our team."
Find us on Facebook for more insight, analysis and the latest in drug store news.
FDA approves generic cancer drug
SILVER SPRING, Md. — The Food and Drug Administration has approved a generic version of a cancer drug in a move that the agency said would help relieve shortages.
The FDA announced the approval of Sun Pharma Global’s doxorubicin hydrochloride liposome injection, a generic version of Johnson & Johnson’s Doxil. The drug is currently on the agency’s list of drugs experiencing shortages.
"The agency is committed to doing everything we can to address drug shortages so that patients can get the medicines they need when they need them," FDA director of drug shortage staff Valerie Jensen said. "For the past year, the FDA has been working to ensure that supplies of doxorubicin hydrochloride liposome injection were not interrupted."
In February 2012, the agency allowed temporary, controlled importation of a version of the drug made abroad.